

RENALYTIX AI

13 July 2020

Renalytix AI plc
("RenalytixAI", the "Company")

Result of General Meeting

Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled *in vitro* diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that all resolutions proposed at the General Meeting held earlier today were duly passed.

The resolutions were duly approved by shareholders on a poll. The results of the poll are as follows:

Resolution	Votes For	% of Shares Voted	Votes Against	% of Shares Voted	% of ISC voted	Votes Withheld
1. Allotment of shares (ordinary resolution)	38,486,100	99.96	15,728	0.04	64.80	814
2. Approval of the 2020 ESPP (ordinary resolution)	38,500,260	99.99	2,382	0.01	64.80	0
3. Approval of the 2020 EIP (ordinary resolution)	32,363,912	84.06	6,137,916	15.94	64.80	814
4. Disapplication of pre-emption rights (special resolution)	38,483,901	99.95	17,927	0.05	64.80	814

Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution.

Defined terms in this release have the same meaning as in the circular sent by the Company to its shareholders on 25 June 2020.

For further information, please contact:

Renalytix AI plc
James McCullough, CEO

www.renalytixai.com
Via Walbrook PR

Stifel (Nominated Adviser)
Alex Price / Nicholas Moore

Tel: 020 7710 7600

Walbrook PR Limited
Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303